Patent US5776094A successfully refreshed from Google Patents.
US5776094A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and kit for imaging and treating organs and tissues
Assignee: Immunomedics Inc
•
Filing: 1995-06-01
•
Granted: 1998-07-07
•
Expires: 2015-06-01
Abstract
Abstract Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.
Inventors
- 👤 Milton David Goldenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:52
CPC Classifications
G; G01; G01R; G01R33/00; G01R33/20; G01R33/44; G01R33/48; G01R33/54; G01R33/56; G01R33/5601; A; A61; A61K; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K51/1027; A61K51/1036; A61K51/1039; A61K51/1045; A61K51/1057; A61K51/1072; A61P; A61P35/00; A61P37/00; A61P37/02; A61P37/06; A61P43/00; B; B82; B82Y; B82Y5/00; A61K2123/00; Y; Y10; Y10S; Y10S424/00; Y10S424/81; Y10S530/00; Y10S530/868
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
180 words
A method of imaging anatomically displaced organs or ectopic cells or tissues in a mammalian subject by scintigraphic or magnetic resonance imaging, comprising (a) parenterally injecting a mammalian subject, at a locus and by a route providing access to an organ or to cells or tissues characteristic of said organ of interest, with an antibody or antibody fragment which specifically binds a marker produced by or associated with said cells or tissues, said antibody or antibody fragment being labeled with a radioisotope or with a magnetic resonance image enhancing agent capable of external detection, the amount of the labeled antibody or antibody fragment being sufficient to permit a scintigraphic or an enhanced magnetic resonance image of said organ, cells or tissue to be obtained; and (b) obtaining a positive scintigraphic image or positive enhanced magnetic resonance image of said organ, cells or tissues, at a time after injection of said agent sufficient for said agent to specifically bind to said marker and, where it is desired to observe the anatomical position of an organ, to diffusely accrete in said organ.
Claim 2
Independent Claim
180 words
A method of imaging anatomically displaced organs or ectopic cells or tissues in a mammalian subject by scintigraphic or magnetic resonance imaging, comprising (a) parenterally injecting a mammalian subject, at a locus and by a route providing access to an organ or to cells or tissues characteristic of said organ of interest, with an antibody or antibody fragment which specifically binds a marker produced by or associated with said cells or tissues, said antibody or antibody fragment being labeled with a radioisotope or with a magnetic resonance image enhancing agent capable of external detection, the amount of the labeled antibody or antibody fragment being sufficient to permit a scintigraphic or an enhanced magnetic resonance image of said organ, cells or tissue to be obtained; and (b) obtaining a positive scintigraphic image or positive enhanced magnetic resonance image of said organ, cells or tissues, at a time after injection of said agent sufficient for said agent to specifically bind to said marker and, where it is desired to observe the anatomical position of an organ, to diffusely accrete in said organ.
Claim 3
Dependent Claim
99 words
The method of claim 1, wherein the cell or tissue is pretargeted with a first composition comprising a streptavidin-conjugated antibody, biotinylated antibody to be used in conjunction with avidin and biotin, bifunctional antibody, antibody-hapten complexes, or enzyme-conjugated antibody, wherein the antibody is an antibody or antibody fragment which specifically binds a marker produced by or associated with said cell or tissue, and after the first composition accretes at the targeted tissue or cell, a second composition, which bears the imaging principle, is administered which activates the first composition or couples with the first composition to produce a desired effect.
Claim 4
Dependent Claim
79 words
The method of claim 2, wherein the cell or tissue is pretargeted by injecting the subject with a first composition which comprises a biotinylated antibody or fragment or an avidin-conjugated antibody or fragment, optionally injecting the patient with a clearing composition comprising an agent to clear circulating biotinylated or avidin-conjugated antibody or fragment, injecting avidin when the first composition is a biotinylated antibody, and then injecting the second composition which comprises biotin conjugated with isotope or mri enhancing agent.
Claim 5
Dependent Claim
13 words
The method of claim 1, wherein the isotope emits at 50-1,500 kev energy.
Claim 6
Dependent Claim
23 words
The method of claim 1, wherein the mri enhancing agent is a species of Gadolinium, Iron, Manganese, Rhenium, Europium, Lanthanium, Holmium or Ferbium.
Claim 7
Dependent Claim
23 words
The method of claim 1, wherein the antibody is a Fv, single chain antibody, Fab, Fab', or F(ab') 2 fragment or intact antibody.
Claim 8
Dependent Claim
33 words
The method of claim 1, wherein the antibody or fragment has a specific immunoreactivity to targeted cells or tissues of at least 60% and a cross-reactivity to other antigens of less than 35%.
Claim 9
Dependent Claim
19 words
The method of claim 1, wherein said cells or tissues to be imaged are anatomically displaced cells or tissues.
Claim 10
Dependent Claim
18 words
The method of claim 1, wherein said cells or tissues to be imaged are ectopic cells or tissues.
Claim 11
Dependent Claim
16 words
The method of claim 9, wherein said cells or tissues to be imaged are endometrial tissues.
Claim 12
Dependent Claim
23 words
The method of claim 1, wherein the mri enhancing agent is a species of Gadolinium, Iron, Manganese, Rhenium, Europium, Lanthanum, Holmium or Terbium.
Claim 13
Dependent Claim
23 words
The method of claim 1, wherein the antibody is a Fv, single chain antibody, Fab, Fab', or F(ab') 2 fragment or intact antibody.
Claim 14
Dependent Claim
35 words
The method of claim 1, wherein the antibody or fragment has a specific immunoreactivity to targeted cells or tissues of at least 60 % and a cross-reactivity to other antigens of less than 35 %.
Claim 15
Dependent Claim
16 words
The method of claim 1, wherein said antibody or fragment is a monoclonal antibody or fragment.
Claim 16
Independent Claim
173 words
A method of imaging a hypoplastic organ or hypoplastic cells or tissues in a mammalian subject by scintigraphic or magnetic resonance imaging, comprising (a) parenterally injecting a mammalian subject, at a locus and by a route providing access to an organ or to cells or tissues of interest, with an antibody or antibody fragment which specifically binds a marker produced by or associated with said cells or tissues, said antibody or antibody fragment being labeled with a radioisotope or with a magnetic resonance image enhancing agent capable of external detection, the amount of the labeled antibody or antibody fragment being sufficient to permit a scintigraphic or an enhanced magnetic resonance image of said organ, cells or tissues be obtained; and (b) obtaining a positive scintigraphic image or positive enhanced magnetic resonance image of said organ, cells or tissues, at a time after injection of said agent sufficient for said agent to specifically bind to said marker and, where it is desired to observe hypoplasia of an organ, to diffusely accrete in said organ.
Claim 17
Independent Claim
173 words
A method of imaging a hypoplastic organ or hypoplastic cells or tissues in a mammalian subject by scintigraphic or magnetic resonance imaging, comprising (a) parenterally injecting a mammalian subject, at a locus and by a route providing access to an organ or to cells or tissues of interest, with an antibody or antibody fragment which specifically binds a marker produced by or associated with said cells or tissues, said antibody or antibody fragment being labeled with a radioisotope or with a magnetic resonance image enhancing agent capable of external detection, the amount of the labeled antibody or antibody fragment being sufficient to permit a scintigraphic or an enhanced magnetic resonance image of said organ, cells or tissues be obtained; and (b) obtaining a positive scintigraphic image or positive enhanced magnetic resonance image of said organ, cells or tissues, at a time after injection of said agent sufficient for said agent to specifically bind to said marker and, where it is desired to observe hypoplasia of an organ, to diffusely accrete in said organ.
Claim 18
Dependent Claim
15 words
The method of claim 15, wherein said imaging is used in diagnosis of juvenile diabetes.
Claim 19
Dependent Claim
17 words
The method of claim 15, wherein said imaging is used in diagnosis of thymic aplasia or agenesis.
Claim 20
Dependent Claim
15 words
The method of claim 15, wherein said imaging is used in diagnosis of DiGeorge's syndrome.
Claim 21
Dependent Claim
100 words
The method of claim 15, wherein the cell or tissue is pretargeted with a first composition comprising a streptavidin-conjugated antibody, biotinylated antibody to be used in conjunction with avidin and biotin, bifunctional antibody, antibody-hapten complex, or enzyme-conjugated antibody, wherein the antibody is an antibody or antibody fragment which specifically binds a marker produced by or associated with said organ, cells or tissues, and after the first composition accretes at the targeted tissue or cell, a second composition, which bears the imaging principle, is administered which activates the first composition or couples with the first composition to produce a desired effect.
Claim 22
Dependent Claim
79 words
The method of claim 19, wherein the cell or tissue is pretargeted by injecting the subject with a first composition which comprises a biotinylated antibody or fragment or an avidin-conjugated antibody or fragment, optionally injecting the patient with a clearing composition comprising an agent to clear circulating biotinylated or avidin-conjugated antibody or fragment, injecting avidin when the first composition is a biotinylated antibody, and then injecting the second composition which comprises biotin conjugated with isotope or mri enhancing agent.
Claim 23
Dependent Claim
13 words
The method of claim 15, wherein the isotope emits at 50-1,500 kev energy.
Claim 24
Dependent Claim
16 words
The method of claim 15, wherein said antibody or fragment is a monoclonal antibody or fragment.
References Cited (Backward Citations)
US3927193A
Cited
US4036945A
Cited
EP0028092A2
Cited
US4444744A
Cited
US4348376A
Cited
US4361544A
Cited
US4331647A
Cited
US4732864A
Cited
US5082928A
Cited
US4735210A
Cited
US5053491A
Cited
US4859449A
Cited
EP0330201A2
Cited
US5223241A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-07-06 | 2002-01-05 | 2002-07-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-07-06 | 2006-01-05 | 2006-07-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-07-06 | 2010-01-05 | 2010-07-07 | $7700.00 | Window Closed / Lapsed |